Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
A Phase 2 Randomized Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog Semaglutide Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Early time points (days to 1-2 weeks) can assess acute effects on barrier function and swelling
If you take both, you are essentially doubling the burden on your digestive system
Semaglutide is the active ingredient in Ozempic, functioning as a GLP-1 (glucagon-like peptide-1) receptor agonist
Clinical data shows weight loss continues accelerating through months 4-6, with the fastest rate of loss occurring during weeks 12-24
Glycemic control, assessed by HbA1c, showed a trend toward lower values in the GLP-1 RA group (6.1% vs 7.0%, p = 0.08), which may have contributed to improved tear film stability and production, although this difference was not statistically significant and cannot solely explain the ocular surface differences
